The global market for Neuromodulation is estimated at US$6.7 Billion in 2023 and is projected to reach US$12.3 Billion by 2030, growing at a CAGR of 9.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the neuromodulation market is driven by several factors. Firstly, the increasing prevalence of chronic and debilitating conditions such as chronic pain, depression, and neurological disorders has heightened the demand for more effective treatment options. Furthermore, increasing aging population globally, and growing awareness of the efficacy and safety of neurostimulator devices are aiding the market. Secondly, technological advancements have significantly improved the efficacy, safety, and patient acceptance of neuromodulation therapies. Innovations such as minimally invasive surgical techniques and the development of smaller, more durable devices have made these treatments more accessible and appealing to a broader patient population. Thirdly, the growing body of clinical evidence supporting the effectiveness of neuromodulation in improving patient outcomes is fostering greater acceptance among healthcare providers and insurers, further propelling market growth. Lastly, an aging global population is contributing to an increased incidence of neurological and chronic pain conditions, thus expanding the potential patient base for neuromodulation therapies. These factors, combined with continuous research and development efforts, underscore the robust and dynamic nature of the neuromodulation market.
The growth in the neuromodulation market is driven by several factors. Firstly, the increasing prevalence of chronic and debilitating conditions such as chronic pain, depression, and neurological disorders has heightened the demand for more effective treatment options. Furthermore, increasing aging population globally, and growing awareness of the efficacy and safety of neurostimulator devices are aiding the market. Secondly, technological advancements have significantly improved the efficacy, safety, and patient acceptance of neuromodulation therapies. Innovations such as minimally invasive surgical techniques and the development of smaller, more durable devices have made these treatments more accessible and appealing to a broader patient population. Thirdly, the growing body of clinical evidence supporting the effectiveness of neuromodulation in improving patient outcomes is fostering greater acceptance among healthcare providers and insurers, further propelling market growth. Lastly, an aging global population is contributing to an increased incidence of neurological and chronic pain conditions, thus expanding the potential patient base for neuromodulation therapies. These factors, combined with continuous research and development efforts, underscore the robust and dynamic nature of the neuromodulation market.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Spinal Cord Stimulation segment, which is expected to reach US$5.4 Billion by 2030 with a CAGR of a 9.2%. The Deep Brain Stimulation segment is also set to grow at 9.5% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $3.1 Billion in 2023, and China, forecasted to grow at an impressive 10.8% CAGR to reach $898.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Neuromodulation Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Neuromodulation Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Neuromodulation Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Abbott Laboratories, Inc., Boston Scientific Corporation, Aleva Neurotherapeutics SA, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 83 Featured):
- Abbott Laboratories, Inc.
- Boston Scientific Corporation
- Aleva Neurotherapeutics SA
- Bioness Inc.
- Beijing Pins Medical Co., Ltd.
- Axonics Modulation Technologies, Inc.
- Biegler GmbH
- Cirtec Medical Corporation
- Cala Health
- BioControl Medical Ltd.
- Atlantic Therapeutics Group Limited
- Bio-Medical Research Limited
- Capitol Pain Institute
- Autonomix Medical
- Bioinduction
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories, Inc.
- Boston Scientific Corporation
- Aleva Neurotherapeutics SA
- Bioness Inc.
- Beijing Pins Medical Co., Ltd.
- Axonics Modulation Technologies, Inc.
- Biegler GmbH
- Cirtec Medical Corporation
- Cala Health
- BioControl Medical Ltd.
- Atlantic Therapeutics Group Limited
- Bio-Medical Research Limited
- Capitol Pain Institute
- Autonomix Medical
- Bioinduction
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 298 |
| Published | October 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 6.7 Billion |
| Forecasted Market Value ( USD | $ 12.3 Billion |
| Compound Annual Growth Rate | 9.1% |
| Regions Covered | Global |
